Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | LDLR | P01130 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24986351 | 0.93 | GABRA5 (0.31) | GABRA5CFTRMAPK13MAPK12MAPK11 | |
| SCHEMBL24986352 | 0.93 | GABRA5 (0.31) | GABRA5CFTRMAPK13MAPK12MAPK11 | |
| SCHEMBL25116391 | 0.93 | GABRA5 (0.31) | GABRA5CFTR | |
| SCHEMBL25116421 | 0.93 | GABRA5 (0.31) | GABRA5CFTR | |
| SCHEMBL25116478 | 0.92 | GABRA5 (0.31) | GABRA5LDLRKITPCSK9 | |
| SCHEMBL25116394 | 0.92 | GABRA5 (0.31) | GABRA5CFTR | |
| SCHEMBL25116519 | 0.92 | GABRA5 (0.31) | GABRA5CFTR | |
| SCHEMBL25116444 | 0.92 | GABRA5 (0.30) | GABRA5 | |
| SCHEMBL25116516 | 0.92 | GABRA5 (0.30) | GABRA5 | |
| SCHEMBL26527290 | 0.89 | HDAC1 (0.33) | GABRA5CFTRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | GABRA5 3773/4885LDLR 3720/4885KIT 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.